Cell therapies first reached patients as treatments for blood cancers. Adaptimmune Therapeutics’ work in this therapeutic modality has culminated in an FDA nod in synovial sarcoma, a regulatory ...
A new study published in the journal Nature reports results of the first-in-human phase 1 clinical trials of a novel immunotherapy approach for solid tumors expressing glypican-3 (GPC3). Researchers ...
The illustration highlights the strengths of mechanical dissociation in preserving the native tumor microenvironment and ensuring viability, alongside the advantages of enzymatic digestion for ...
Chimeric Antigen Receptor (CAR) T cell therapies have revolutionized cancer treatment—but so far, their success has been largely limited to blood cancers. Solid tumors, which account for around 90% of ...
Today some of the most aggressive solid tumor cancers remain stubbornly resistant to treatment. There are many reasons why these cancers are difficult to treat, including mutations they may express or ...
WALTHAM, Mass.--(BUSINESS WIRE)--Minerva Biotechnologies published “Effective CAR T cell targeting of a MUC1 cleavage product” in the Journal for ImmunoTherapy of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results